Current knowledge on treatment of chronic hepatitis B in children.
So far the treatment of chronic hepatitis B has been based on the use of numerous agents, particularly interferon alpha which proved the most effective. Attempts are made to introduce new therapeutic methods (antiviral agents--nucleoside analogues, immunotherapy--anti HBV vaccine, gene therapy) in order to obtain higher percentage of patients with durable inhibition of HBV replication than it is observed after treatment with interferon alpha. The current work has been devoted to the presentation of the experiences with interferon alpha, lamivudine and anti HBV vaccine used in subjects with chronic type B hepatitis, with special reference to paediatric patients.
Lebensztejn
D M
DM
3rd Department of Paediatric Diseases, Medical University, ul. Waszyngtona 17, 15-274 Bialystok, Poland.
Kaczmarski
M
M
D000998:Antiviral Agents / Q000627:therapeutic use; D002648:Child; D017325:Hepatitis B Vaccines / Q000627:therapeutic use; D019694:Hepatitis B, Chronic / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D011994:Recombinant Proteins
D000998:Antiviral Agents; D017325:Hepatitis B Vaccines; D007370:Interferon Type I; D011994:Recombinant Proteins; D019259:Lamivudine